Epax has launched a full-spectrum oil offering a unique combination of Omegas 3, 9 and 11, with particular potential for skin health supplements.

EPAX^® Omega 3-9-11 is rich in Omega-3 EPA and DHA – long-chain poly-unsaturated fatty acids (LC-PUFAs) well known for their benefits in areas like heart and brain health. However, unlike other Omega-3 products, it combines them with the less familiar long-chain monounsaturated fatty acids (LC-MUFAs), Omegas 9 and 11, which are increasingly being recognised for their potential in skin and metabolic health.

The first concentrated version of an oil with both LC-MUFAs and LC-PUFAs, EPAX^® Omega 3-9-11 is derived from pelagic fish from the North Atlantic. As well as a healthy amount of Omega-3, they contain unusually high levels of Omega-9 and Omega-11.

The new product is produced using Epax^® EQP+ Tech, a next-level distillation process, which allows Epax to isolate and increase the content of Omegas 3, 9 and 11. EPAX^® Omega 3-9-11 contains a minimum of 720 mg / g of these fatty acids.

Ideal for nutraceuticals, it offers significant potential in the skin health category. EPA and DHA are capable of reducing UV-induced inflammation , while a pilot study by Epax has indicated that Omega-9 and Omega-11-rich cetoleic oils can reduce skin redness.

Furthermore, there is evidence that the different fatty acids in EPAX^® Omega 3-9-11 may work together to deliver a complementary effect. In preclinical studies, metabolic health parameters were improved to a greater extent with a combination of LC-MUFAs and LC-PUFAs than with each lipid on its own.

Bjørn Refsum, CEO of Epax, said: “Omega-3 fatty acids – and all the scientific evidence of their benefits – are just the start of the story. As well as developing EPA and DHA of unmatched purity and quality, Epax has been exploring the potential of other marine lipids. EPAX^® Omega 3-9-11 is a full-spectrum solution that offers the best of both worlds – the familiar, well-proven Omega-3 and the up-and-coming Omegas 9 and 11. The potential is huge, and there’s much more to discover.”

Epax is supporting further research into the role of LC-MUFAs in skin health. Recruitment has begun for a randomised placebo-controlled study in subjects with eczema. Epax is also proud to provide LC-MUFAs for university research into metabolic health.

Learn More or use the green "Request Information" button below to ask for details.

References

1. Pilkington et al, 2011
2. Yoshinaga et al, 2021